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Crystal Structure of Mycoplasma arthritidis Mitogen
Complexed with HLA-DR1 Reveals a Novel Superantigen
Fold and a Dimerized Superantigen-MHC Complex
coccal enterotoxins (SEs), staphylococcal toxic shock
syndrome toxin-1 (TSST-1), and streptococcal pyro-
genic exotoxins (SPEs). Although the crystal structures
of several SAgs were reported (see reviews, Li et al.,
1999; Mitchell et al., 2000; Sundberg et al., 2002a), our
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Canada ity binding site, have been identified on MHC (Hudson
et al., 1995). The SAgs SEA (Petersson et al., 2002), SEB
(Jardetzky et al., 1994), SEC3 (Sundberg et al., 2002b),
and TSST-1 (Kim et al., 1994) share a partially overlap-Summary
ping low-affinity binding site on the MHC 1 domain.
SEA, SEB, and SEC3 do not contact the bound peptidesMycoplasma arthritidis-derived mitogen (MAM) is a
in the “groove” of the MHC class II molecules, whereassuperantigen that can activate large fractions of T cells
TSST-1 seems to cover a portion of the C-terminal partbearing particular TCR V elements. Here we report
of the bound peptide. In contrast, SPEC and SEH bind,the crystal structure of MAM complexed with a major
each via a zinc ion, in slightly varying orientations to thehistocompatibility complex (MHC) antigen, HLA-DR1,
high-affinity binding site on the MHC  chain (Li et al.,loaded with haemagglutinin peptide 306-318 (HA). The
2001; Petersson et al., 2001) and make extensive con-structure reveals that MAM has a novel fold composed
tacts with the N-terminal portion of the bound peptides.of two -helical domains. This fold is entirely different
In addition, some SAgs can form zinc-dependent homo-from that of the pyrogenic superantigens, consisting
dimers (Al-Daccak et al., 1998; Langlois et al., 2003),of a -grasped motif and a  barrel. In the complex,
which could in turn dimerize the MHC class II moleculesthe N-terminal domain of MAM binds orthogonally to
on the APC surface (Al-Daccak et al., 1998). It has beenthe MHC 1 domain and the bound HA peptide, and
proposed that dimerization or oligomerization of theto a lesser extent to the MHC 1 domain. Two MAM
MHC antigens by SAgs is critical for both T cell activationmolecules form an asymmetric dimer and cross-link
and T cell-independent cytokine expression on varioustwo MHC antigens to form a plausible, dimerized
human APCs (Mehindate et al., 1995). Although a hypo-MAM-MHC complex. These data provide the first crys-
thetical model of a SEA1-MHC2 complex was recentlytallographic evidence that superantigens can dimerize
proposed on the basis of the crystal structure of a SEAMHC molecules. Based on our structure, a model of
mutant in complex with MHC (Petersson et al., 2002), athe TCR2MAM2MHC2 complex is proposed.
dimerized SAg-MHC complex has not yet been de-
scribed crystallographically.
Introduction Mycoplasma arthritidis-derived mitogen (MAM) is pro-
duced by Mycoplasma arthritidis (Cole, 1991). MAM can
Superantigens (SAgs) are immunoregulatory proteins induce spontaneous chronic arthritis in genetically sus-
generally produced by bacteria and viruses (Kotzin et ceptible strains of rodents that resembles human rheu-
al., 1993; Li et al., 1999). Upon their binding to the MHC matoid arthritis. Although MAM functions like a conven-
class II molecules, SAgs are recognized by TCR in a tional SAg, it does not share significant global sequence
V-restricted fashion, resulting in polyclonal activation homology with other SAgs (Cole et al., 1996). Like other
of a large pool of T lymphocytes (up to 20%). Their SAgs, MAM interacts with TCR in a V-restricted fash-
discovery offered hopes for effective T cell-based thera- ion. However, in contrast to other SAgs, MAM binding
pies, provided insight into some diseases caused by is influenced by the TCR CDR3 (Hodtsev et al., 1998),
SAgs and, more importantly, proved to be an effective suggesting that MAM represents a new type of ligand
tool for studying interactions within the trimolecular for TCR, distinct from both conventional peptide anti-
complex: MHC class II/peptide/TCR. gens and other known SAgs. It was recently observed
The best-characterized group of SAgs belongs to the that MAM preferentially binds to HLA-DR1 with high
pyrogenic toxin SAg family from Staphylococcus aureus affinity comparable to murine MHC class II (Etongue-
and Streptococcus pyogenes, which include staphylo- Mayer et al., 2002).
In this study, we report the crystal structure, at 2.6 A˚
resolution, of MAM complexed with a MHC class II mole-*Correspondence: lih@wadsworth.org
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Figure 1. Overall Structure of the HLA-DR1/HA/MAM Complex
(A) A dimerized MAM-MHC complex in the asymmetric unit. Two pairs of phosphate groups are shown in ball-and-stick representation at
each complex interface.
(B) Ribbon diagram of MAM dimer. The N- and C termini of MAM-2 are labeled with N and C, respectively. The elements contributing to the
dimer interface are labeled, including 5 (1), loop 5-6 (2), 8 (4), and loop 8-9 (3) from MAM-1, and 2 (7), 4 (2), 8 (2) and 9 (2) from
MAM-2. The number in parentheses indicates the number of residues contributed to the dimer interface.
(C) A single HLA-DR1/HA/MAM complex, showing the overall geometry between HLA-DR1 and MAM. The 1, 2, 1, and 2 domains of HLA-
DR1 are labeled. A pair of phosphate groups is shown in ball-and-stick representation at the interface. Each component is colored as follows:
MAM, red; the DR1  domain, cyan; the DR1  domain, blue; the HA peptide, magenta. The N-terminal loop of MAM (1–25) is colored orange.
(D) Stereoview of a representative (2Fo-Fc) electron density map, contoured at 1.0 , at the complex interface, showing the HA peptide
(magenta), MAM (green), phosphate groups (yellow). Here and in the following figures (unless otherwise specified), atoms are colored as
follows: carbon, yellow; nitrogen, blue; oxygen, red; phosphate, green. Residues are labeled for the HA peptide (magenta) and MAM (black).
(E) Stereoview ribbon diagram of MAM monomer showing the overall fold and secondary structure elements of MAM with every tenth residue
labeled. The ten  helices, including 1 (25–35), 2 (41–65), 3 (71–93), and 4 (96–125) from the N-terminal domain, and 5 (126–146), 6
(157–168), 7 (170–175), 8 (176–195), 9 (199–203), and 10 (204–211) from the C-terminal domain, are labeled. The N- and C termini are
labeled as N and C, respectively. Asn125, which is shared by 4 and 5 helices and covalently connects the N- and C-terminal domains, is
labeled. The N-terminal loop (1–25) is colored orange.
cule, HLA-DR1, loaded with haemagglutinin peptide and thus represents a new family of SAgs. In the com-
plex, the N-terminal domains of MAM interact orthogo-306-318 (HA). Our results show that MAM adopts a novel
fold composed of two completely -helical domains, nally with the antigen-presenting domains of the MHC
Crystal Structure of MAM Complexed with Peptide/MHC
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Table 1. Data Collection, SAD Phasing, and Refinement Statistics
Data collection and SAD phasing
Average
Data Wavelength (A˚) Resolution (A˚) Redundancy Completeness (%) I/(I) Rsym (%) Rano (%) Se Sites FOM
Native 1.03 3.3 2.1 81.3 (74.0)a 7.4 (3.9) 11 (43.9)
SAD1 0.978 3.4 4.7 99.5 (99.9) 12.7 (5.3) 13.9 (33.4) 6.8 6 0.09
SAD2 0.979 2.6 3.6 95.9 (80.4) 15 (2.1) 8.0 (48.9)
Refinement
Non-H Atoms Rmsd
Resolution (A˚) No. of Reflections Rwork Rfree Protein Water PO43 Average B Distance Angle
100–2.6 65311 23.8% 24.6% 9888 106 4 45.7 A˚2 0.008 A˚ 1.4
a Values in parentheses are those for the highest resolution shell.
molecules. Two MAM molecules form an asymmetric The scaffold of the C-terminal domain is most similar
to that of the N-terminal domain of bacteriophage pro-dimer through the C-terminal domains of MAM. The
MAM dimer cross-links two HLA-DR1/HA complexes to capsid protein gpD (Dokland et al., 1997), in which one
central helix is surrounded by six others. Three pairs ofform a dimerized MAM-MHC complex, providing the
first crystallographic evidence that superantigens can the helices, including 5, 6, and 8 in MAM and 1,
3, and 4 in gpD, can be superimposed, resulting indimerize MHC molecules.
an rmsd of 2.2 A˚ for 40 C pairs.
Although MAM is a two-domain structure, each do-Results and Discussion
main is tightly packed against the other (Figure 1E). The
helix 5 from the C-terminal domain folds back towardOverall Structure of the MAM/HA/
HLA-DR1 Complexes the N-terminal helical bundle, making 5 almost perpen-
dicular to 4. The domain association buries a total ofThe structure was solved by a combination of molecular
replacement and single-wavelength anomalous diffrac- 1201 A˚2 of solvent-accessible surface (SAS) area (calcu-
lated using a probe of 1.4 A˚), with equal contributionstion (SAD) phasing methods (Figure 1A; Table 1). All
parts of the complex structure were well ordered. A from both domains. At the domain interface, there are
12 hydrogen bonds including two salt bridges (data notrepresentative electron density map is shown (Figure
1D). In the final refined model, two MAM/HA/HLA-DR1 shown), suggesting that MAM forms a rigid structure.
The crystal structure of the MAM/HA/DR1 complexcomplexes form an asymmetric dimer (Figure 1A). Each
MAM/HA/DR1 complex comprises residues 1–181 of the clearly reveals that MAM adopts a novel fold that is
entirely different from those of other pyrogenic SAgs.DR1  chain, 1–190 of the DR1  chain, 306–318 of the HA
peptide, 1–213 of MAM, a serine residue from the GST To date, more than a dozen SAgs have been structurally
characterized. Except Urtica dioica agglutinin, a planttag, and two phosphate groups. In addition, 106 water
molecules were included in the final model. lectin with superantigenic activity (Saul et al., 2000), all
other SAgs of known structure are from the pyrogenic
SAg family. The typical structure of a pyrogenic SAg isThe Novel Superantigen Fold
As shown in Figure 1E, MAM displays a completely composed of two domains, defined as large and small.
The large domain consists of a central helix resting-helical structure that consists of ten  helices. The
overall structure of MAM monomer is L-shaped and is against a four-stranded  sheet, which is known as a
-grasped motif (Mitchell et al., 2000). The small domaincomposed of two domains. Topology analysis, using
the SCOP database (Murzin et al., 1995) and the Web is a five-stranded  barrel of oligonucleotide/oligosac-
charide binding fold (Mitchell et al., 2000). In contrast,servers TOP (Lu, 2000) and VAST (Gibrat et al., 1996),
showed that there is no published fold similar to the the structure of MAM is completely -helical, represent-
ing a novel SAg fold and a new type of ligand for TCR.overall structure of MAM. However, the structures of
individual N- and C-terminal domains are similar to the
known folds. The central feature of the N-terminal do- The MAM Homodimer and Dimerized
MAM/MHC Complexmain (residues 1–125) is a four--helical bundle (Figure
1E), which is similar to many functionally unrelated four- Although size-exclusion chromatography showed that
MAM exists as a monomer in solution at micromolarhelical proteins. Database searches indicated that the
bundle is most similar to that of bacteriorhodopsin concentration (data not shown), cross-linking experi-
ments have suggested that MAM can form a zinc-depen-(Luecke et al., 1998) (root-mean-square deviation [rmsd]
of 2.7 A˚ for 80 C pairs) and to that of E. coli L-aspartate dent dimer in solution (Langlois et al., 2003). Indeed,
there are two HLA-DR1/HA/MAM complexes in theammonia-lyase (Shi et al., 1997) (rmsd of 2.9 A˚ for 79
C pairs). Beyond the bundle, the N terminus of MAM asymmetric unit in the crystal. Two MAM molecules form
a dimer bridging two MHC molecules (Figure 1A). Al-is a long loop of 25 residues (1–25), which wraps around
the -helical bundle (Figures 1C, 1E, and 2C). The C-ter- though the MAM dimer is formed through a nearly per-
fect pseudo 2-fold symmetry (177 rotation), the twominal domain (126–213) contains six helices (Figure 1E).
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MAM molecules, termed MAM-1 and MAM-2, interact the dimer association. In addition, the shape correlation
statistic (Sc) (Lawrence and Coleman, 1993) of 0.64 forasymmetrically (Figure 1B). Overall, the C-terminal do-
mains of MAM molecules play a major role in dimer the dimer interface is comparable to the value for anti-
body-antigen complexes (0.64–0.75) (Li et al., 2003), in-formation. In particular, the C-terminal domain of MAM-1
interacts with both the N- and C-terminal domains of dicating a good shape complementarity between the
two monomers. These data suggest that the dimer asso-MAM-2, whereas the C-terminal domain of MAM-2 only
contacts the C-terminal domain of MAM-1. ciation in the crystal structure represents a physiological
form of MAM dimer existing in solution, although crystal-At the dimer interface, the C-terminal domain of
MAM-1 fits into a V-shaped pocket between the two packing effects may not be completely ruled out.
In the crystal the MAM homodimer bridges two MHCdomains of MAM-2 (Figure 1B). There are 24 residues
from both molecules involved in the dimer interface. molecules to form a dimerized MAM-MHC complex (Fig-
ure 1A). This dimerized complex may represent a veryHowever, only one residue, Asp 197, is used in common,
but involving different interactions. Asp 197 from MAM-1 plausible arrangement under physiological condition
because the C termini of the two MHC molecules informs a hydrogen bond with His58 of MAM-2, whereas
Asp197 from MAM-2 forms van der Waals contacts with the complex dimer are oriented in the same direction,
indicating that they can be anchored on the surface ofArg154 of MAM-1 (Figure 2A). For MAM-1, all 11 residues
at the dimer interface are from the C-terminal domain. the same APC. Thus our crystal structure provides the
first crystallographic evidence that the SAgs can indeedIn contrast, 13 residues from MAM-2 involved in the
dimer association are contributed by both domains, al- dimerize MHC class II molecules.
though the N-terminal domain plays the major role by
contributing two-thirds of the interactions. Most of the
The MAM/HA/DR1 Interface: Overall Viewresidues at the dimer interface are polar residues, but
of the Complexonly four hydrogen bonds occur (Figure 2A). The main
Each MAM molecule of the MAM dimer interacts withhydrophobic contacts are contributed by Ile144, Tyr193,
one class II MHC HLA-DR1/HA complex in the sameand Tyr194 from MAM-1, and Leu50 from MAM-2. Other
fashion (Figure 1A). In fact, structure superposition ofinteractions include mainly side chain stacking contacts
the two MAM/HA/HLA-DR1 complexes in the asymmet-through the aliphatic portions of the polar residues (Fig-
ric unit results in an rmsd of 0.36 A˚ for 597 C pairs.ure 2A).
Therefore, although the results and further discussionThe total buried surface area of 1818 A˚2 at the dimer
will be based on the conformation of complex 1 (Figureinterface falls within the average range of 1600  400 A˚2
1C), the conclusions will be generally applicable to com-observed for protein-protein interactions (Lo Conte et
plex 2 as well.al., 1999). Each MAM monomer contributes the buried
In the complex structure, the MAM/HA/DR1 interac-SAS area roughly equivalently (MAM-1 [53%] and
tion buries 2208 A˚2 of SAS area by an equal contributionMAM-2 [47%]) of about 900 A˚2, representing 7% of the
from MAM and the HLA-DR1/HA complex. This totaltotal surface area of 12,642 A˚2 for a MAM monomer.
buried surface area is the largest observed among theAlthough 46 residues contribute to the buried surface
known SAg/MHC complexes (Jardetzky et al., 1994; Kimarea, only 7, including Arg154, Arg192, Tyr194, Glu195,
et al., 1994; Li et al., 2001; Petersson et al., 2001, 2002).and Asp197 from MAM-1, and Leu50 and Lys201 from
The interface is also larger than that in the TCR/peptide/MAM-2, make large contributions, totaling about 43%
MHC complexes (1800 A˚2) (Garcia et al., 1999) or thatof the buried surface area.
in most antibody-antigen interfaces (1600  400 A˚2) (LoAlthough it was reported that zinc ion may be involved
Conte et al., 1999). The Sc value of 0.69 for the MAM/in MAM/MHC interaction or in the formation of a zinc-
HA/DR1 interface is similar to that for other SAg/MHCdependent MAM homodimer (Etongue-Mayer et al.,
complexes (0.62–0.65) and is higher than that for most2002; Langlois et al., 2003), no zinc ion could be located
TCR/peptide/MHC complexes (0.46–0.70) (Li et al.,at the current structure. In addition, a cross-linking ex-
1999). It reflects a good shape complementarity. Consis-periment using disuccinimidyle glutarate (DSG) sug-
tently, MAM binds to HLA-DR1 in high affinity of nano-gested that a portion of MAM exists as a dimer regard-
molar range (Etongue-Mayer et al., 2002).less of the presence of zinc ions (data not shown).
The contacting interface is composed of 27 residuesTherefore, the exact role of zinc ion for MAM function
from MAM, 20 from the DR1  chain, 6 from the DR1 needs further investigation.
chain, and 9 from the bound HA peptide (Table 2). SixAs discussed above, the interactions at the dimer
of the residues from MAM and DR1 molecules, includinginterface are asymmetric. The asymmetric association
Lys39, Leu60, Gln12m, His14m, Phe15m, and Val85m,of the dimer is not due to the internal domain flexibility
individually make large contributions of more than 80 A˚2of MAM. Although the two domains of MAM were refined
to the buried SAS area. (Here and in the following unlesswith two independent groups of noncrystallographic
otherwise specified, suffixes after residue numbers sig-symmetry (NCS) restraints, the two MAM molecules in
nify as follows: , the DR1  chain; , the DR1  chain;the asymmetric unit are almost identical, with an rmsd
and m, MAM). These results are consistent with theof 0.09 A˚ for all 213 C pairs. Through crystal packing,
finding that synthetic MAM peptides composed of resi-each MAM molecule interacts identically with two MHC
dues 14–31 or 11–38 can inhibit MAM binding to themolecules (Figure 4A). Therefore, except at the dimer
HLA-DR1 molecule (Etongue-Mayer et al., 2002; Knudt-interface, the two MAM monomers face essentially the
son et al., 1997). In addition, a double mutant of MAM, insame environment, implying that crystal-packing inter-
actions may not be the determinant factor in affecting which His14 and Asp31 were both changed to alanines,
Crystal Structure of MAM Complexed with Peptide/MHC
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Figure 2. Details of MAM Dimer Interface and MAM/HA/DR1 Interface Shown as Stereoviews
In all three panels, the letter before the residue number represents the chain name in the crystal structure.
(A) MAM homodimer interface. MAM-1 is colored gray, and MAM-2 is colored green. Key residues are depicted as ball-and-stick representations
with bonds and carbon atoms colored as follows: MAM-1, yellow; MAM-2, green. Residues are color-labeled black and red for MAM-1 and
MAM-2, respectively. The four hydrogen bonds, including Arg154 N2-Arg192 N1, Tyr193 O-Lys51 N, Gly196 O-His58 N	1, and Asp197
O-Gln54 N
2, are shown as orange dashed lines.
(B and C) Detailed views of HLA-DR1/HA/MAM interfaces, showing hydrogen bonds and hydrophobic interactions. The ribbon diagram of
each component in the complex is colored as follows: MAM, light blue; peptide, magenta; HLA-DR1, gray. Key residues are displayed as ball-
and-stick representations with bonds and carbon/phosphate atoms colored as follows: MAM, green; the HA peptide, magenta; HLA-DR1,
yellow; PO43, cyan. Hydrogen bonds are shown as orange dashed lines. Residues are color-labeled as follows: MAM, black; HLA-DR1, blue;
peptide, magenta; phosphate, red.
failed to trigger the activation of T cell hybridomas ex- area, 16 residues cover up more than 70% of their SAS
area upon complex formation (Table 2). These resultspressing V8.1 and V6 (Langlois et al., 2003). The dou-
ble-mutant MAM can activate the Kmls hybridoma ex- are consistent with mutagenesis and biochemical data.
For example, synthetic peptides encompassing MAMpressing V15.8, although it does so less efficiently than
does the wild-type. This implies that other regions of residues 76–90 or 71–95 can inhibit the binding between
MAM and HLA-DR1 (Etongue-Mayer et al., 2002; Knudt-MAM must play a role in MAM-DR1 recognition. Indeed,
although individually contributing less buried surface son et al., 1997). On the other hand, triple mutations at
Structure
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Table 2. Interactions between HLA-DR1/HA and MAM
MAM
Hydrogen Bondsa Van der Waals Contactsb
HLA-DR1
Tyr13c (7, 88%)d O Asp88 (58, 91%) O	2 Asp88
Asp17 (20, 30%) O Lys92 (48, 30%) N
Gln18 (68, 61%) O
1 Arg91 (28, 25%) N1 Asp88, Arg91, Lys92
N
2 Arg91 N1
N
2 Asp88 O	1
O Lys92 N
Ala37 (69, 73%) O Gln99 (29, 85%) N
2 Thr89 (40, 78%), Gln99
Lys38 (47, 36%) Arg102 (57, 43%)
Lys39 (91, 67%) N Glu109 (56, 49%) O
1 Ile106 (64, 90%), Glu109
Gln57 (49, 39%) O
1 Lys82 (57, 79%) N Lys82, Glu109, Lys113 (19, 27%)
Leu60 (81, 86%) Val85 (80, 91%), Ile106
Ala61 (45, 83%) Met78 (17, 57%)
Asn62 (5, 100%) His14 (100, 91%)
Ile63 (11, 85%) Val85
Ala64 (55, 98%) Leu81 (42, 76%), Lys82, Val85,
Val65 (41, 98%) His14, Met78
Lys67 (51, 65%) N Ser84 (22, 55%) O Ser84, Asp88
N Asp88
N Ser84 O
Ala68 (36, 72%) Leu81
Tyr60 (43, 43%) O Gln17 (7, 12%) O
1
Gln64 (23, 31%) Phe15 (131, 96%)
Asp66 (38, 30%) Lys13 (32, 33%)
Leu67 (51, 73%) Phe15
HA peptide
P3 Lys (26, 44%) N Gln12 (84, 61%) O
1 Gln12
P5 Asn (59, 94%) N	2 Lys13 O Gln12, Lys13, His14
P6 Thr (11, 100%) O His14 N	1 His14
P7 Leu (21, 72%) Lys13, His14, Phe15
P8 Lys (104, 97%) N His14 O His14, Phe15, Asn18,
N Asn18 (56, 48%) O	1 Leu19 (29, 40%)
N Asn18 N	2 Val 16 (18, 100%)
HLA-DR1/HA MAM
First PO43
O1 His14 N
2
Gln12 O
O2 Lys113 N
Asp117 O	1
O3 P3 Lys N
O4 Gln12 N
Asp117 O	1
Second PO43
O1 P3 Lys N
a Hydrogen bonds were calculated using a 2.5–3.4 A˚ donor-acceptor distance.
b Van der Waals contacts 4 A˚.
c Residues that bury more than 80 A˚2 or that bury more than 70% of their SAS area upon complex formation are indicated in bold face.
d Values in parentheses indicate the buried solvent-accessible surface area (A˚2) and the percentile.
the DR1 residues Ile63, Val65, and Ala68 resulted in is in agreement with the findings for other complexes
between SAg and MHC, SAg and TCR, and TCR andthe loss of presentation of MAM to T cells (Etongue-
Mayer et al., 2002), while two other mutations at Val42 MHC (Li et al., 1999), suggesting that conformational
change is not a mechanism for MAM to trigger T celland Glu46, which are not at the MAM/HA/DR1 inter-
face, do not affect the presentation of MAM to T cells activation.
(Etongue-Mayer et al., 2002).
One pair of phosphate groups was found at equivalent The MAM/HA/DR1 Interface: Interactions
between MAM and HLA-DR1positions of the edge of each complex interface (Experi-
mental Procedures). The phosphate groups in the crystal The MAM/HA/DR1 complex is formed through contacts
between the N-terminal domain of MAM and the antigen-structure may contribute to the stabilization of the local
structure of the complex (Table 2), although the exact presenting domain of HLA-DR1 (Figure 1C). The site on
HLA-DR1/HA recognized by MAM is composed of fourfunction of the phosphate is unclear.
Upon complex formation, there are no major structural components: (1) the loops between strands 1 and 2
(L1) and between 3 and 4 (L3) of the DR1  chain; (2)changes at the interface in the structure of MHC, which
Crystal Structure of MAM Complexed with Peptide/MHC
283
the 1 helix of the DR1  chain; (3) the HA peptide; The three hydrophobic patches (Figures 2B and 2C)
are clustered at the center of the complex interface.and (4) the 1 helix of the DR1  chain. The structural
elements of MAM at the MAM/HA/DR1 interface mainly They are surrounded by 19 hydrogen bonds, involving
both main chain and side chain atoms (Table 2). Mostinvolve the N-terminal loop (1–25) and helices 3 and
4. With the tip of the MAM helical bundle pointing away of the hydrogen bonds, including those in which only
MAM residues are completely buried upon complex for-from the MHC groove, helices 3 and 4 of the bundle
interact orthogonally with the 1 helix of the DR1  chain mation (Lys82m N-Gln57 O
1, Asp88m O	1-Gln18
N
2, Asp88m O	1-Lys67 N, and Asp88m O	2-Tyr13(Figure 1C). The DR1 helix 1 evidently acts as a roller
bearing to support the MAM helices. In addition, helices O), are at the periphery of the interface (Figures 2B
and 2C).3 and 4 of MAM contact the MHC L1 and L3 loop
regions (Figure 1C). Although helices 3 and 4 are
distant from the peptide binding groove, the N-terminal The MAM/HA/DR1 Interface: Interactions
loop of MAM fills the space between the HA peptide between MAM and the HA Peptide
and MAM helices 3 and 4 (Figure 1C). The middle The MAM and HLA-DR1 molecules together contribute
portion of the loop, composed of MAM residues 12–18, about 89% of the total buried surface area, and the
is located directly above and runs nearly parallel to the remaining 11% is contributed by the bound HA peptide
HA peptide, creating both hydrogen bonds and van der (Figure 2C; Table 2). Upon complex formation, 246 A˚2
Waals contacts with the peptide. The loop further ex- of the SAS area of the HA peptide is buried. Nearly half
tends interactions with the 1 helix of the DR1  chain of this (104 A˚2) is contributed by one residue, P8 Lys
(Figures 1C and 2C). The C-terminal domain of MAM (Table 2). In addition to P8 Lys, P5 Asn, P6 Thr, and P7
is oriented upward and away from the MHC class II Leu bury more than 70% of their SAS area upon complex
molecule, consistent with the observation that a syn- formation (Table 2).
thetic peptide composed of MAM C-terminal residues At the interface, a substantial number of contacts exist
197–211 did not inhibit MAM binding to the HLA-DR1 between the bound HA peptide and MAM. The HA pep-
molecule (Etongue-Mayer et al., 2002). In addition, the tide contributes 43 contacts to the interaction. These
structure agrees very well with results of truncation stud- account for about one-third of the total contacts be-
ies (Langlois et al., 2000). Two C-terminal-truncated tween MAM and the HLA-DR1/HA molecules. In addition
MAM molecules, terminated at 132 and 176, respec- to the hydrophobic contribution of P7 Leu, the HA pep-
tively, kept their ability to bind the MHC class II mole- tide forms six hydrogen bonds, including two salt brid-
cules, although they failed to stimulate the activation of ges, with MAM (Table 2). The hydrogen bonds between
T cell hybridomas. His14m O-P8 Lys N and His14m N	1-P6 Thr O (Table 2;
Table 2 lists the interactions between MAM and HLA- Figure 2C) are the only two completely buried ones out
DR1/HA at the complex interface. Of the 26 residues of the 19 hydrogen bonds at the interface. Indeed, muta-
that either make large surface contributions or bury a tion of MAM residue His14 disrupts MAM binding to
large percentage of the SAS area upon complex forma- class II MHC molecules (Etongue-Mayer et al., 2002).
tion, 15, including P7 Leu from the HA peptide, are hy- The results suggest that MAM is, at least in part, a
drophobic and 11 are hydrophilic. This implies that hy- peptide-dependent SAg.
drophobic interactions play a major role in the formation
of the MAM/HA/DR1 complex. The hydrophobic inter-
Structural Comparison with Otherface can be divided into three “patches” (Figures 2B
SAg-MHC Complexesand 2C). In the first hydrophobic patch, MAM residue
Although they have very different structures, MAM andPhe15m fits into a small hydrophobic pocket created
the pyrogenic SAgs share similar binding sites on theby hydrophobic residues Tyr60, Trp61, and Leu67,
MHC  chain (Figures 3A, 3C, and 3D). The binding siteand the aliphatic part of Gln64 of the DR1  chain
on the HLA-DR1 molecule for MAM is most similar to(Figure 2C). In addition, the HA residue, P7 Leu, is part of
that for TSST-1 (Figures 3A and 3D), although the totalthe hydrophobic base for Phe15m (P7 refers the seventh
buried surface area in the MAM/DR1 complex is nearlyresidue from the first anchor residue [P1] for the bound
double of that in the TSST-1/DR1 complex. On the otherpeptide in the MHC “groove”). The second hydrophobic
hand, the surface property of MAM and TSST-1 as wellpatch is above the 1 helix of the DR1  chain, facing
as SEB for binding to MHC is very similar. For instance,the peptide binding groove. Residues involved in this
at one portion of the hydrophobic interface, the TSST-1patch include Val16m, Leu19m, Met78m, and Leu81m
residues are Ile42, Leu44, Ile81, and Phe83, which corre-of MAM, and Ala61, Ala64, Val65, Ala68, and Ile72
spond to the MAM residues Leu19, Leu81, Leu16, andof the DR1 1 helix (Figure 2C). The first and second
Met78, respectively. At another portion of the hydropho-hydrophobic patches are separated by five hydrogen
bic interface, SEB residues Phe44 and Tyr89 are re-bonds between MAM and the HA peptide (Figure 2C;
placed by Val85 and Ile106 in MAM, respectively. TheTable 2). The second hydrophobic patch extends be-
Tyr89→Ile106 replacement results in the loss of a hydro-yond the DR1 1 helix to form the third hydrophobic
philic pocket accommodating the MHC residue, Lys39,patch. The interactions at the third patch involve the
in the SEB/DR1 and TSST-1/DR1 complexes, in whichMAM residues Val85, Val86, and Ile106, and the DR1
Lys39 is deeply buried at the interface and is involvedresidues Tyr13, Met36, Leu60, Ile63, and Ala64
in buried hydrogen bonds. Consistently, the lysine resi-(Figure 2B). The second and third patches are connected
due is very important for the binding of both SEB andthrough residue Ala64 of HLA-DR1 and together form
a large, curved hydrophobic surface. TSST-1 to MHC. In contrast, the pocket in the MAM-
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Figure 3. Surface Representation of the Binding Sites for Representative SAgs and TCRs on MHC/Peptide Complexes
Surface representation of the binding sites for representative SAgs and TCRs on MHC in complexes, including (A) MAM/HA/HLA-DR1; (B)
TCR/HA/HLA-DR1; (C) SEB/HLA-DR1; (D) TSST-1/HLA-DR1; (E) SPEC/MBP/HLA-DR2a. The antigen-presenting domains (1 and 1) of MHC
are optimally superimposed. The buried surface area is colored green. The bound peptides within or out of the binding sites are colored using
atomic colors as follows: carbon, yellow; oxygen, red; nitrogen, blue. The N- and C termini and the P5 position of the bound peptides are
labeled.
DR1 complex is filled with Ile106 and Val86. As a result, Nevertheless, the binding site on HLA-DR1 for MAM
overlaps those for the pyrogenic SAgs (Figures 3A, 3C,the side chain of Lys39 rotates away from the interface
but still forms a salt bridge with MAM residue Glu109 and 3D). Consistently, preincubation of THP-1 cells with
SEB, TSST-1, or SEAD227A can completely abolish MAM-at the surface (Figure 2B). Such a salt bridge may be
less important for complex formation than is the buried induced cytokine expression (Bernatchez et al., 1997).
In addition, another SEAF47A mutant, which only binds toone, since it may be replaced by water-mediated hydro-
gen bonds, as demonstrated in the antibody-antigen the DR1  chain, can also block MAM’s activity (Bernat-
chez et al., 1997). This can be explained by the facts thatcomplex (Dall’Acqua et al., 1998). Indeed, mutation of
Lys39 to alanine affects neither the binding affinity the binding site on MHC for MAM partially overlaps
that for SPEC (Li et al., 2001) (Figures 3A and 3E) andbetween MAM and HLA-DR1 nor the ability to stimulate
the activation of T cells (Etongue-Mayer et al., 2002). that SEA shares with SPEC a single high-affinity binding
Crystal Structure of MAM Complexed with Peptide/MHC
285
site on MHC (Li et al., 2001). When the antigen-present- inconsistent with the general concept that SAgs activate
T cells by optimally crosslinking TCR to MHC, resultinging domains in the SPEC/MHC and MAM/MHC com-
plexes are optimally superimposed, SPEC partially over- in the bypass of the normal constrains of the TCR speci-
ficity and MHC restriction, there is increasing evidencelaps MAM (Figures 3A and 3E), to an extent sufficient
to sterically hinder MAM from accessing its binding site to suggest that the bound peptide in the MHC groove
may play a crucial role in modulating SAg activity (Ko-on the MHC  chain.
zono et al., 1995; Wen et al., 1996, 1997). For instance,
it has been found that TSST-1 can be presented to T cells
Comparison with Conventional TCR/MHC 5000-fold stronger by certain peptides than by others.
Complexes: Role of the Bound Peptide Such a peptide dependence may allow SAgs to distin-
Although MAM and TCR have completely different three- guish between different types of APCs, which are likely
dimensional structures, structural comparison of the to display distinct arrays of peptides (Woodland et al.,
HLA-DR1/HA/MAM and HLA-DR1/HA/TCR (Hennecke 1997). Thus, SAgs may be targeted preferentially to den-
et al., 2000) complexes reveals that the binding sites for dritic cells or macrophages and away from cells that
MAM and the TCR HA1.7 on the HLA-DR1 molecule are express more restricted peptide repertoires. The possi-
very similar (Figures 3A and 3B). In the HLA-DR1/HA/ bility is supported by experimental data showing that
TCR complex, the TCR HA1.7 interacts with residues SAgs can be presented differently by identical MHC
39, 57, 58, 61, 65, 67, and 68 of the DR1  chain, all of molecules on different cell types (Yagi et al., 1994). Fur-
which contact MAM in the HLA-DR1/HA/MAM complex. thermore, TSST-1 does not compete with SEB for bind-
On the DR1  chain, MAM contacts with residues 60, ing to HLA-DR1 on APCs (Thibodeau et al., 1994), even
61, 64, 66, 67, and 70, while the TCR HA1.7 interacts though structural studies demonstrate that both SAgs
with residues 64, 66, 69, 70, 77, and 81. bind to overlapping regions on HLA-DR1 (Kim et al.,
Both MAM and TCR contact the bound HA peptide 1994). The peptide dependence of SAgs may also allow
at a comparable level (Figures 3A and 3B). In fact, the SAgs to bind MHC in a high-affinity but low-density
buried surface area by the HA peptide in the MAM/HA/ fashion so as to mimic the low antigen densities in con-
DR1 complex represents about 22% of the total area ventional T cell activation triggered by serial engage-
contributed by the DR1/HA complex and is comparable ment of TCRs (Woodland et al., 1997). Such a low-den-
to that by the antigenic peptides (30%) in the conven- sity binding can ensure that SAgs appropriately activate
tional TCR/peptide/MHC complexes (Garcia et al., T cells at an optimal level, which may be necessary to
1999). avoid the induction of T cell apoptosis resulting from
Structural comparison reveals that MAM and TCR the binding of high ligand densities (Lenardo, 1991;
similarly contact the central portion of the bound HA Woodland et al., 1997).
peptide. This is in contrast to other SAg-MHC com-
plexes of known structures, in which TSST-1, SPEC, or
SEH binds either to the C-terminal or to the N-terminal Hypothetical Model of a TCR2-MAM2-MHC2
Complexregion of the bound peptides, respectively (Kim et al.,
1994; Li et al., 2001; Petersson et al., 2001) (Figures 3D The interaction between MAM and the symmetry-related
MHC molecule results in an alternative MAM/HA/DR1and 3E). Indeed, the TCR HA1.7 “spans” the HA peptide
between residues P-1 and P8, while MAM contacts the complex (Figure 4A). MAM interacts with the 2 domain
of the symmetry-related DR1 molecule. The tip of theHA residues from P3 to P8 (Figures 3A and 3B). There-
fore, both MAM and TCR bind to the central region, at 2 domain binds into a large curved pocket created by
the two domains of MAM. At the cell surface, the tip ofor around the P5 position in the peptide (Figures 3A and
3B). P5 plays a major role in the conventional TCR- the DR1 2 domain should be closely associated with the
cell membrane. The interactions between MAM and thepeptide/MHC recognition (Garcia et al., 1999). In fact,
the HA peptide has very similar conformations in both symmetry-related HLA-DR1 are therefore due to crystal
packing. Although it does not represent a binding siteMAM/MHC and TCR/MHC complexes. Particularly, the
side chain conformation of P5 Asn of the HA peptide for DR1 on MAM, the site on MAM may represent the
binding site for TCR. This proposal is because the MHCis nearly identical in both MAM/MHC and TCR/MHC
complexes (data not shown), whereas it is different from 2 domain carries an immunoglobulin fold in structure
similar to that of a TCR. Indeed, superposition of the Vthat in the unbound form of HLA-DR1/HA. These data
imply that the bound peptide plays a significant role in domain of a human JM22 TCR (V10.2V17) (Stewart-
Jones et al., 2003) onto the C-reversed 2 domain ofthe MAM/MHC recognition. On the other hand, MAM
may mimic the peptide dependence in conventional an- the symmetry-related DR1 gives an rmsd of 2.82 A˚ for
79 C pairs. Therefore, a hypothetical model amongtigen presentation. Therefore, the nature of the peptide
may strongly influence MAM presentation. Consistently, MAM, HLA-DR1, and JM22 TCR can be established (Fig-
ure 4B). In this model no overlap exists between anyimmunological data indicated that MAM binding to MHC
is influenced by the bound peptide (Etongue-Mayer et parts of the three interacting molecules. Several features
of the model are consistent with immunological andal., 2002). When Hela cells were transfected with HLA-
DR1 covalently linked with the HA307-318 peptide, they mutagenesis data. In the model, MAM predominantly
interacts with the TCRchain, although there is possiblepresented MAM poorly. Triple mutations on the HA pep-
tide, in which P5 Asn, P8 Lys, and P11 Thr were mutated interaction between the TCR  chain and MAM. This is
consistent with the ability of the TCR  chain alone toto alanine, significantly increased MAM binding.
Although the peptide dependence of MAM appears bind MAM (Cole, 1991). The TCR contacts both the
Structure
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Figure 4. Model of Dimerized TCR-MAM-MHC Complex
(A) Overall geometry of MAM interaction with the HLA-DR1/HA complexes. The 1, 2, 1, and 2 domains of the symmetry-related HLA-
DR1 molecule are labeled.
(B) A model of the TCR2-MAM2-MHC2 complex. The model was built by superposition of the V17 domain of the JM22 TCR onto the C-reversed
2 domain of the symmetry-related HLA-DR1/HA complex in the crystal structure of the MAM/HA/DR1 complex.
phosphate, 0.1 M HEPES (pH 7.5). Microseeding was used to pro-N- and C-terminal domains of MAM, which agrees well
duce large crystals for both the native and Se-Met complexes forwith results of the truncation studies in which two
X-ray data collection.C-terminal deletion mutants of MAM failed to trigger
T cell activation (Langlois et al., 2000). In addition, the
X-Ray Data Collection, StructureCDR3 loop of the TCR  chain makes contacts with
Determination, and Refinement
MAM. Consistent with this, it is suggested that the CDR3 The crystals belong to space group I222, with unit cell parameters
region influences the binding of MAM to TCR (Hodtsev a  137.35 A˚, b  178.18 A˚, c  179.56 A˚. There are two MAM/HA/
DR1 complexes per asymmetric unit. Prior to data collection, allet al., 1998).
crystals were transferred to a reservoir solution containing 20%A MAM homodimer could cross-link two MHC and two
glycerol and then flash cooled under a nitrogen stream at 100 KTCR molecules to form a TCR2-MAM2-MHC2 complex
and stored in liquid nitrogen. Native data were collected to 3.2 A˚(Figure 4B). In the model, the TCR2-MAM2-MHC2 com- resolution at 100 K using a small crystal at beamline 19-BM of the
plex is mediated by a MAM homodimer. The C termini Advanced Photon Source (APS) (Argonne National Laboratory). All
of the TCRs are directed in opposite directions. This of the data were processed and scaled using HKL2000 (Otwinowski
and Minor, 1997). With the crystal structure of the HLA-DR1/HAmay suggest that MAM could utilize its high-affinity
complex (Stern et al., 1994) as a search model, clear solutions forbinding to the MHC molecules to simultaneously recruit
the HLA-DR1 molecules were obtained using the native data by themultiple T cells, so as to achieve highly efficient T cell
molecular replacement (MR) program AMoRe (Navaza, 1994). Theactivation. Nevertheless, although SAgs and TCR are
resultant electron density maps showed some densities beyond the
engaged very differently in class II MHC-mediated T cell- boundary of the DR1/HA molecules, but were insufficient to enable
signaling complexes, it is remarkable that they achieve of tracing the MAM molecule. Therefore, a set of single anomalous
diffraction (SAD) data for the Se-Met complex crystal was collecteda common end result: highly efficient T cell activation.
to 3.4 A˚ resolution using a synchrotron X-ray source at beamline
X12C (  0.978 A˚) of the National Synchrotron Light Source (NSLS)Experimental Procedures
(Brookhaven National Laboratory). High-resolution SAD data up to
2.5 A˚ resolution were later collected at beamline X25 of NSLS.Protein Production and Crystallization
Soluble MAM was expressed as a GST-fusion protein as described In combining of the phase contribution from the MR solutions of
the MHC molecules, we performed a phased SAD calculation usingpreviously (Langlois et al., 2000). The HLA-DR1/HA complex was
prepared using a refolding protocol as described (Frayser et al., the 3.4 A˚ SAD data with the program SOLVE (Terwilliger and Berend-
zen, 1999). The positions for six Se atoms were clearly defined. With1999). The selenomethionine-substituted (Se-Met) version of the
DR1  chain was purified and then refolded together with the DR1 the combined MR and SAD phase information, noncrystallographic
symmetry (NCS) averaging using the program RESOLVE (Terwilliger, chain and the HA peptide (PKYVKQNTLKLAT). Purified MAM was
concentrated to about 8.8 mg/ml with a buffer of 10 mM Tris-HCl 2001) was able to produce an interpretable map. Fragments con-
taining about 50% of the MAM residues could be automatically(pH 8.0), 100 mM NaCl, 1 mM DTT; the HA/HLA-DR1 complex was
concentrated to 5.4 mg/ml with a buffer of 20 mM HEPES (pH 7.5), traced by the program RESOLVE. The model of a MAM monomer
was finally completed by manually fitting the electron density map100 mM NaCl, 1 mM DTT. For crystallization, the HLA-DR1/HA com-
plex and MAM were mixed in an equimolar ratio. Initial crystallization with the MAM sequence using the program TURBO FRODO (Roussel
and Cambillau, 1989). The second MAM molecule was then gener-conditions were established using sparse matrix screens. Crystals
were grown at room temperature in hanging drops by mixing 2 l ated using the NCS symmetry. The 2.5 A˚ resolution data set, with
7% of the data (4640 reflections) set aside as the test data for theof protein solution in the presence of 1 mM Zn(OAc)2 with an equal
volume of reservoir solution containing 1.7 M potassium sodium Rfree cross-validation, was used to complete the final refinement
Crystal Structure of MAM Complexed with Peptide/MHC
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using CNS (Brunger et al., 1998). Each domain in the MAM/HA/HLA- Cole, B.C. (1991). The immunobiology of Mycoplasma arthritidis and
its superantigen MAM. Curr. Top. Microbiol. Immunol. 174, 107–119.DR1 complexes was refined as an independent rigid body at the
early stage of refinement using the rigid-body refinement option in Cole, B.C., Knudtson, K.L., Oliphant, A., Sawitzke, A.D., Pole, A.,
CNS. Iterative cycles of simulated annealing, positional, tortion Manohar, M., Benson, L.S., Ahmed, E., and Atkin, C.L. (1996). The
angle, and temperature factor (B) refinement were then carried out, sequence of the Mycoplasma arthritidis superantigen, MAM: identi-
interspersed with model rebuilding into A-weighted (Fo-Fc) and (2Fo- fication of functional domains and comparison with microbial super-
Fc) electron density maps. Omit maps for groups of MAM residues antigens and plant lectin mitogens. J. Exp. Med. 183, 1105–1110.
were frequently calculated to check the correct tracing and confor-
Dall’Acqua, W., Goldman, E.R., Lin, W., Teng, C., Tsuchiya, D., Li,mations. In addition, NCS restraints defined by pairs of individual
H., Ysern, X., Braden, B.C., Li, Y., Smith-Gill, S.J., and Mariuzza, R.A.domain were used throughout the refinement. During structure re-
(1998). A mutational analysis of binding interactions in an antigen-finement and model rebuilding, four peaks over 8  were observed
antibody protein-protein complex. Biochemistry 37, 7981–7991.in the (Fo-Fc) electron density maps. The peaks form two pairs. Each
Dokland, T., McKenna, R., Ilag, L.L., Bowman, B.R., Incardona, N.L.,peak is at least 3.7 A˚ away from the closest protein ligand; therefore
Fane, B.A., and Rossmann, M.G. (1997). Structure of a viral procap-it is impossible for these peaks to represent zinc ions that have
sid with molecular scaffolding. Nature 389, 308–313.average distance of 2.09 A˚ between a zinc ion and its ligand. These
densities could be fitted perfectly as phosphate groups (PO43), Etongue-Mayer, P., Langlois, M.A., Ouellette, M., Li, H., Younes, S.,
which are present at a high concentration (1.7 M) in the crystallization Al-Daccak, R., and Mourad, W. (2002). Involvement of zinc in the
buffer. Although the crystals were grown in the presence of 1 mM binding of mycoplasma arthritidis-derived mitogen to the proximity
ZnCl2, zinc ion could not be found at any part of the complex struc- of the HLA-DR binding groove regardless of histidine 81 of the beta
ture, including both the MAM dimer and MAM-DR1 interfaces. Con- chain. Eur. J. Immunol. 32, 50–58.
sistently, an anomalous signal corresponding to the zinc absorption Frayser, M., Sato, A.K., Xu, L., and Stern, L.J. (1999). Empty and
edge could not be detected for the crystals using a synchrotron peptide-loaded class II major histocompatibility complex proteins
X-ray beam (data not shown), implying that zinc ion may not be produced by expression in E. coli, and folding in vitro. Protein Expr.
coordinated into the crystals. Purif. 15, 105–114.
At 2.6 A˚ resolution, the current Rcryst is 23.8% with an Rfree of 24.5%.
Garcia, K.C., Teyton, L., and Wilson, I.A. (1999). Structural basis ofFor the nonglycine residues, 99.8% of the main chain torsion angles
T cell recognition. Annu. Rev. Immunol. 17, 369–397.lie in the most favored or allowed regions of the Ramachandran
Gibrat, J.F., Madej, T., and Bryant, S.H. (1996). Surprising similaritiesplot. Only residues Asn33 of the  chain of HLA-DR1 from both
in structure comparison. Curr. Opin. Struct. Biol. 6, 377–385.complexes in the asymmetric unit fall into the disallowed regions.
This residue, clearly defined in the density map, has a conformation Hennecke, J., Carfi, A., and Wiley, D.C. (2000). Structure of a cova-
very similar to that in the unbound DR1/HA complex (Stern et al., lently stabilized complex of a human alphabeta T-cell receptor, influ-
1994), SEA/HA/DR1 complex (Petersson et al., 2002), or SPEC/MBP/ enza HA peptide and MHC class II molecule, HLA-DR1. EMBO J.
DR2a (Li et al., 2001) complex. It is located within a mixed  turn 19, 5611–5624.
and type II  hairpin, in which unusual main chain torsion angles
Hodtsev, A.S., Choi, Y., Spanopoulou, E., and Posnett, D.N. (1998).
are frequently observed (Li et al., 2000). The refinement statistics
Mycoplasma superantigen is a CDR3-dependent ligand for the T cell
are summarized in Table 1. Atomic coordinates have been deposited
antigen receptor. J. Exp. Med. 187, 319–327.
in the Protein Data Bank as entry 1R5I.
Hudson, K.R., Tiedemann, R.E., Urban, R.G., Lowe, S.C., Strominger,
J.L., and Fraser, J.D. (1995). Staphylococcal enterotoxin A has two
Acknowledgments cooperative binding sites on major histocompatibility complex class
II. J. Exp. Med. 182, 711–720.
This research is supported by a grant (AI50628) from the National
Jardetzky, T.S., Brown, J.H., Gorga, J.C., Stern, L.J., Urban, R.G.,Institute of Health (NIH) (to H.L.). We thank R.A. Mariuzza, G. Wins-
Chi, Y.I., Stauffacher, C., Strominger, J.L., and Wiley, D.C. (1994).low, and P. Van Roey for critical readings of the manuscript, L.J.
Three-dimensional structure of a human class II histocompatibilityStern for the gift of HLA-DR1 expression plasmids, and the Peptide
molecule complexed with superantigen. Nature 368, 711–718.Synthesis Core facility at the Wadsworth Center for the synthesis
Kim, J., Urban, R.G., Strominger, J.L., and Wiley, D.C. (1994). Toxicof the HA peptide. We thank R.G. Zhang at APS, and R. Sweet and
shock syndrome toxin-1 complexed with a class II major histocom-M. Becker at NSLS for assistance in X-ray data collection. The X-ray
patibility molecule HLA-DR1. Science 266, 1870–1874.diffraction facilities at the APS and NSLS are supported by the
Department of Energy and by grants from NIH. Knudtson, K.L., Manohar, M., Joyner, D.E., Ahmed, E.A., and Cole,
B.C. (1997). Expression of the superantigen Mycoplasma arthritidis
mitogen in Escherichia coli and characterization of the recombinantReceived: September 10, 2003
protein. Infect. Immun. 65, 4965–4971.Revised: October 15, 2003
Kotzin, B.L., Leung, D.Y., Kappler, J., and Marrack, P. (1993). Super-Accepted: October 16, 2003
antigens and their potential role in human disease. Adv. Immunol.Published: February 10, 2004
54, 99–166.
Kozono, H., Parker, D., White, J., Marrack, P., and Kappler, J. (1995).References
Multiple binding sites for bacterial superantigens on soluble class
II MHC molecules. Immunity 3, 187–196.
Al-Daccak, R., Mehindate, K., Damdoumi, F., Etongue-Mayer, P.,
Langlois, M.A., Etongue-Mayer, P., Ouellette, M., and Mourad, W.Nilsson, H., Antonsson, P., Sundstrom, M., Dohlsten, M., Sekaly,
(2000). Binding of Mycoplasma arthritidis-derived mitogen to humanR.P., and Mourad, W. (1998). Staphylococcal enterotoxin D is a
MHC class II molecules via its N terminus is modulated by invariantpromiscuous superantigen offering multiple modes of interactions
chain expression and its C terminus is required for T cell activation.with the MHC class II receptors. J. Immunol. 160, 225–232.
Eur. J. Immunol. 30, 1748–1756.
Bernatchez, C., Al-Daccak, R., Mayer, P.E., Mehindate, K., Rink, L.,
Langlois, M.A., El Fakhry, Y., and Mourad, W. (2003). Zinc-bindingMecheri, S., and Mourad, W. (1997). Functional analysis of Myco-
sites in the N terminus of Mycoplasma arthritidis-derived mitogenplasma arthritidis-derived mitogen interactions with class II mole-
permit the dimer formation required for high affinity binding to HLA-cules. Infect. Immun. 65, 2000–2005.
DR and for T cell activation. J. Biol. Chem. 278, 22309–22315.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P.,
Lawrence, M.C., and Coleman, P.M. (1993). Shape complementarityGrosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M.,
at protein/protein interfaces. J. Mol. Biol. 234, 946–950.Pannu, N.S., et al. (1998). Crystallography & NMR system: a new
software suite for macromolecular structure determination. Acta Lenardo, M.J. (1991). Interleukin-2 programs mouse alpha beta T
lymphocytes for apoptosis. Nature 353, 858–861.Crystallogr. D Biol. Crystallogr. 54, 905–921.
Structure
288
Li, H., Llera, A., Malchiodi, E.L., and Mariuzza, R.A. (1999). The enhanced stimulation of a CD4 tumor-infiltrating lymphocyte line.
J. Mol. Biol. 319, 449–461.structural basis of T cell activation by superantigens. Annu. Rev.
Immunol. 17, 435–466. Terwilliger, T.C. (2001). Maximum-likelihood density modification
using pattern recognition of structural motifs. Acta Crystallogr. DLi, Y., Li, H., Smith-Gill, S.J., and Mariuzza, R.A. (2000). Three-dimen-
Biol. Crystallogr. 57, 1755–1762.sional structures of the free and antigen-bound Fab from mono-
clonal antilysozyme antibody HyHEL-63(,). Biochemistry 39, 6296– Terwilliger, T.C., and Berendzen, J. (1999). Automated structure so-
6309. lution for MIR and MAD. Acta Crystallogr. D Biol. Crystallogr. D55,
849–861.Li, Y., Li, H., Dimasi, N., McCormick, J.K., Martin, R., Schuck, P.,
Schlievert, P.M., and Mariuzza, R.A. (2001). Crystal structure of a Thibodeau, J., Cloutier, I., Lavoie, P.M., Labrecque, N., Mourad,
superantigen bound to the high-affinity, zinc-dependent site on W., Jardetzky, T., and Sekaly, R.P. (1994). Subsets of HLA-DR1
MHC class II. Immunity 14, 93–104. molecules defined by SEB and TSST-1 binding. Science 266, 1874–
1878.Li, Y., Li, H., Yang, F., Smith-Gill, S.J., and Mariuzza, R.A. (2003).
X-ray snapshots of the maturation of an antibody response to a Wen, R., Cole, G.A., Surman, S., Blackman, M.A., and Woodland,
protein antigen. Nat. Struct. Biol. 10, 482–488. D.L. (1996). Major histocompatibility complex class II-associated
peptides control the presentation of bacterial superantigens toLo Conte, L., Chothia, C., and Janin, J. (1999). The atomic structure
T cells. J. Exp. Med. 183, 1083–1092.of protein-protein recognition sites. J. Mol. Biol. 285, 2177–2198.
Wen, R., Broussard, D.R., Surman, S., Hogg, T.L., Blackman, M.A.,Lu, G. (2000). TOP: a new method for protein structure comparisons
and Woodland, D.L. (1997). Carboxy-terminal residues of major his-and similarity searches. J. Appl. Crystallogr. 33, 176–183.
tocompatibility complex class II-associated peptides control the
Luecke, H., Richter, H.T., and Lanyi, J.K. (1998). Proton transfer
presentation of the bacterial superantigen toxic shock syndrome
pathways in bacteriorhodopsin at 2.3 angstrom resolution. Science
toxin-1 to T cells. Eur. J. Immunol. 27, 772–781.
280, 1934–1937.
Woodland, D.L., Wen, R., and Blackman, M.A. (1997). Why do super-
Mehindate, K., Thibodeau, J., Dohlsten, M., Kalland, T., Sekaly, R.P.,
antigens care about peptides? Immunol. Today 18, 18–22.
and Mourad, W. (1995). Cross-linking of major histocompatibility
Yagi, J., Uchiyama, T., and Janeway, C.A., Jr. (1994). Stimulator cellcomplex class II molecules by staphylococcal enterotoxin A super-
type influences the response of T cells to staphylococcal enterotox-antigen is a requirement for inflammatory cytokine gene expression.
ins. J. Immunol. 152, 1154–1162.J. Exp. Med. 182, 1573–1577.
Mitchell, D.T., Levitt, D.G., Schlievert, P.M., and Ohlendorf, D.H.
Accession Numbers(2000). Structural evidence for the evolution of pyrogenic toxin su-
perantigens. J. Mol. Evol. 51, 520–531.
Atomic coordinates have been deposited in the Protein Data Bank
Murzin, A.G., Brenner, S.E., Hubbard, T., and Chothia, C. (1995). as entry 1R5I.
SCOP: a structural classification of proteins database for the investi-
gation of sequences and structures. J. Mol. Biol. 247, 536–540.
Navaza, J. (1994). AmoRe: an automated package fro molecular
replacemnt. Acta Crystallogr. A 50, 157–163.
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction
data collected in oscillation mode. Methods Enzymol. 276, 307–326.
Petersson, K., Hakansson, M., Nilsson, H., Forsberg, G., Svensson,
L.A., Liljas, A., and Walse, B. (2001). Crystal structure of a superanti-
gen bound to MHC class II displays zinc and peptide dependence.
EMBO J. 20, 3306–3312.
Petersson, K., Thunnissen, M., Forsberg, G., and Walse, B. (2002).
Crystal structure of a SEA variant in complex with MHC class II
reveals the ability of SEA to crosslink MHC molecules. Structure 10,
1619–1626.
Roussel, A., and Cambillau, C. (1989). TURBO FRODO. In Silicon
Graphics Geometry Partners Directory, (Mountain View, CA: Silicon
Graphics), pp. 77–78.
Saul, F.A., Rovira, P., Boulot, G., Damme, E.J., Peumans, W.J.,
Truffa-Bachi, P., and Bentley, G.A. (2000). Crystal structure of Urtica
dioica agglutinin, a superantigen presented by MHC molecules of
class I and class II. Struct. Fold. Des. 8, 593–603.
Shi, W., Dunbar, J., Jayasekera, M.M., Viola, R.E., and Farber, G.K.
(1997). The structure of L-aspartate ammonia-lyase from Esche-
richia coli. Biochemistry 36, 9136–9144.
Stern, L.J., Brown, J.H., Jardetzky, T.S., Gorga, J.C., Urban, R.G.,
Strominger, J.L., and Wiley, D.C. (1994). Crystal structure of the
human class II MHC protein HLA-DR1 complexed with an influenza
virus peptide. Nature 368, 215–221.
Stewart-Jones, G.B., McMichael, A.J., Bell, J.I., Stuart, D.I., and
Jones, E.Y. (2003). A structural basis for immunodominant human
T cell receptor recognition. Nat. Immunol. 4, 657–663.
Sundberg, E.J., Li, Y., and Mariuzza, R.A. (2002a). So many ways of
getting in the way: diversity in the molecular architecture of superan-
tigen-dependent T-cell signaling complexes. Curr. Opin. Immunol.
14, 36–44.
Sundberg, E.J., Sawicki, M.W., Southwood, S., Andersen, P.S.,
Sette, A., and Mariuzza, R.A. (2002b). Minor structural changes in
a mutated human melanoma antigen correspond to dramatically
